ARS Pharmaceuticals, Inc. (SPRY) — key financial figures for fiscal year 2025 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2025)

$84.3M

Net Income/Loss (FY2025)

-$171.3M

Total Assets (FY2025)

$327.7M

Total Equity (FY2025)

$114.3M

Cash Flows from Operating Activities (FY2025)

-$170.9M

Source: ARS Pharmaceuticals, Inc. 10-K filing (FY2025). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.